[1]顾益凤,朱自力,史跃燕,等.血浆硫氧还蛋白还原酶水平检测对宫颈癌早期诊断的价值研究[J].现代检验医学杂志,2019,34(02):40-43.[doi:10.3969/j.issn.1671-7414.2019.02.011]
　GU Yi-feng,ZHU Zi-li,SHI Yue-yan,et al.Study on the Value of Plasma Thioredoxin Reductase Levelin the Early Diagnosis of Cervical Cancer[J].Journal of Modern Laboratory Medicine,2019,34(02):40-43.[doi:10.3969/j.issn.1671-7414.2019.02.011]
点击复制

血浆硫氧还蛋白还原酶水平检测对宫颈癌早期诊断的价值研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第34卷
期数:
2019年02期
页码:
40-43
栏目:
论著
出版日期:
2019-05-11

文章信息/Info

Title:
Study on the Value of Plasma Thioredoxin Reductase Levelin the Early Diagnosis of Cervical Cancer
文章编号:
1671-7414(2019)02-040-04
作者:
顾益凤; 朱自力; 史跃燕; 刘红利
(南通市肿瘤医院检验科,江苏南通 226361)
Author(s):
GU Yi-feng; ZHU Zi-li; SHI Yue-yan; LIU Hong-li
(Department of Clinical Laboratory, Nantong Tumor Hospital,Jiangsu Nantong 226361,China)
关键词:
宫颈癌;  宫颈上皮内瘤变;  硫氧还蛋白还原酶;  鳞状细胞癌抗原
分类号:
R737.33; R730.43
DOI:
10.3969/j.issn.1671-7414.2019.02.011
文献标志码:
A
摘要:
目的 检测和分析血浆硫氧还蛋白还原酶(thioredoxin redyctase,TrxR)在宫颈癌和宫颈上皮内瘤变(cervical intraepithelial neoplasia,CIN)患者中的水平变化,探讨其在宫颈癌早期辅助诊断中的价值。方法 选取2018年1～9月在南通市肿瘤医院确诊的78例宫颈癌和18例CIN患者及同期20例健康对照者的血浆,记录患者临床资料。运用酶联免疫吸附法(enzyme-linked immunosorbnent assay,ELISA)检测血浆TrxR浓度; 同时对以上实验者的血浆用电化学发光法(electrochemical luminescence immunoassay,ECL)检测鳞状细胞癌抗原(squamous cell carcinoma antigen,SCCA)。统计分析二者对宫颈癌早期诊断的价值以及血浆TrxR与宫颈癌临床病理参数间的关系。结果 健康对照组、CIN组和宫颈癌组TrxR水平分别为2.46(0.98,4.21)μg/L,4.38(1.26,6.37)μg/L和5.98(4.02,15.01)μg/L,CIN组TrxR水平较健康对照组显著升高(U=33.5),宫颈癌组TrxR水平较健康对照组也显著升高(U=17.0),差异均有统计学意义(P<0.001)。健康对照组、CIN组和宫颈癌组SCCA水平分别为1.34(0.52,2.06)μg/L,1.61(0.72,2.34)μg/L和7.12(2.76,20.53)μg/L,CIN组较健康对照组SCCA水平升高,差异有统计学意义((U=48.1,P<0.01),宫颈癌组SCCA水平较健康对照组显著升高,差异有统计学意义(U=27.2,P<0.001)。受试者工作曲线(receiver operating characteristic curve,ROC)显示血浆TrxR诊断宫颈癌的曲线下面积(aera under curve,AUC)是0.840(95%CI:0.761～0.902),敏感度和特异度分别为92.3%和68.4%,约登指数为60.7%。而血浆SCCA诊断宫颈癌的AUC是0.822(95%CI:0.740～0.886),敏感度和特异度分别为65.4%和86.8%,约登指数为52.2%。病理分期I/II期与III/IV期相比,TrxR水平差异无统计学意义(U=662.0,P=0.500 4),SCCA水平两组间差异有统计学意义(U=452.0,P=0.004 8)。宫颈癌患者TrxR水平与年龄、病理类型和FIGO分型无关(均P>0.05),而与细胞分化程度相关(U=496.0,P=0.034)。结论 TrxR水平的检测有助于宫颈癌及宫颈上皮内瘤变的早期诊断,对于宫颈癌的早期预警和及早干预有着积极的意义。
Abstract:
Objective To discuss the clinical significanceof plasma TrxR in the early diagnosis of cervical cancer by testing and analyzing its level in cervical intraepithelial neoplasia(CIN)and cervical cancer.Methods Plasma samples were collected from 78 patients withcervical cancer and 18 patients with cervical cancer in Nantong Tumor Hospital from January 2018 and September 2018,at the same time plasma from 20 healthycontrols were collected.The clinical data of patients were recorded.The levelof plasma TrxR was measured by enzyme-linked immunosorbnent assay(ELISA),while SCCA was measured by electrochemical luminescence immunoassay(ECL)method.Their diagnostic significance was evaluated.The relationship between TrxR and clinical parameters of cervical cancer was analyzed.Results The levels of TrxR in healthy control group,CIN group and cervical cancer group were 2.46(0.98,4.21)μg/L,4.38(1.26,6.37)μg/L and 5.98(4.02,15.01)μg/L,respectively.The level of TrxR in CIN group were significantly higher than thosein healty control group(U=33.5),and TrxR levels in cervical cancer groupat were also significantly higher than those in healthy control group(U=17.0),both the difference was ststistically significant(P<0.001).The SCCA levels in healthy control group,CIN group and cervical cancer group were 1.34(0.52,2.06)μg/L,1.61(0.72,2.34)μg/L and 7.12(2.76,20.53)μg/L,respectively,the level of SCCA in CIN group was higher than those in healthy control group(U=48.1),and the difference was statistically significant(P<0.01).The level of SCCA in cervical cancer group was significantly higher than those in healthy control group(U=27.2),and the difference was statistically significant(P<0.001).Receiver operating characteristic(ROC)curve showed that the area under curve(AUC)of plasma TrxR was 0.840(95%CI:0.761～0.902),thesensitivity and specificity was 92.3% and 68.4%,and the Youden index was 60.7%.The AUC of plasma SCCA was 0.822(95%CI:0.740～0.886),the sensitivityand specificity was 65.4% and 86.8%,and the Youden index was 52.2%.PlasmaTrxR in patients with cervical cancer was no difference between I/II stages andIII/IV stages(U=662.0,P=0.500 4),while plasma SCCA had significance difference between I/II stages and III/IV stages(U=452.0,P=0.004 8).Thelevel of plasma TrxR was no correlated with ages,histological type and FIGO stages(P>0.05); while there was significant association with cell differentiation(U=496.0,P=0.034).Conclusion Detection of plasma TrxR level contributes to the early diagnosis of cervical cancer and CIN,what's more,it has positive significance for early warning and early intervention of cervical cancer.

参考文献/References:

[1] SUH D H,KIM J W,KANG S,et al.Major clinical research advances in gynecologic cancer in 2013[J].J Gynecol Oncol,2014,25(3):236-248.
[2] HWANG-BO H,JEONG J W,HAN M H,et al.Auranofin,an inhibitor of thioredoxin reductase,induces apoptosis in hepatocellular carcinoma Hep3B cells by generation of reactive oxygen species[J].Gen.Physiol.Biophys,2017,36(2):117-128.
[3] METERE A,FREZZOTTI F,GRAVE C E,et al.A possible role for selenoprotein glutathione peroxidase(GPx1)and thioredoxin reductases(TrxR1)in thyroid cancer: our experience in thyroid surgey[J].Cancer Cell International,2018,18:7.
[4] YAN Xiang,ZHANG Xiaoshan,WANG Li,et al.Inhibition of thioredoxin/thioredoxin reductase induces synthetic lethality in lung cancers with compromised glutathione homeostais[J].Cancer Research,2019,79(1):125-132.
[5] ZHU GE Weishan,CHEN Ruijie,VLADIMIR K,et al.Costunolide specificallybinds and inhibits thioredoxin reductase 1 to induce apoptosis in colon cancer[J].Cancer Letters,2018,412:46-58.
[6] 田英,王双勇,赵雅,等.宫颈癌组织细胞中Numb基因表达及相关性研究[J].现代检验医学杂志,2015,30(6):42-45. TIAN Ying,Wang Suangyong,Zhao Ya,et al.Study on correlation andexpression of numb gene in cervical cancer[J].J Mod Lab Med,2015,30(6):42-45.
[7] 王冰,朱月蓉,何玉杰,等.血清结合珠蛋白在宫颈癌诊断中的应用研究[J].现代检验医学杂志,2017,32(1):106-108. WANG Bing,ZHU Yuerong,HE Yujie,et al.Application of haptoglobinin cervical cancer diagnosis[J].J Mod Lab Med,2017,32(1):106-108.
[8] KOHARYOVA M,KOLLAROVA M.Thioredoxin system-a novel therapeutic target[J].Gen Physiol Biophys,2015,34(3):221-233.
[9] DONG Chaoran,ZHANG Lei,SUN Ruoxuan,et al.Role of thioredoxin reductase 1 in dysplastic transformation of human breast epithelial cells triggered bychronic oxidative stress[J].Sci Rep,2016,6:36860.
[10] LI Chunyan,PENG Yan,MAO Binglang,et al.Thi-oredoxin reductase:A novel,independent prognostic marker in patients with hepatocellular carcinoma[J].Oncotarget,2015,6(19):17792-17804.
[11] CHEN Gong, CHEN Qiong, ZENG Fanxu,et al.The serum activity of thioredoxin reductases 1(TrxR1)is correlated with the poor prognosis in EGFR wild-type and ALK negative non-small cell lung cancer[J].Oncotarget,2017,8(70):115270-115279.
[12] KEMERDERE R,KACIRA T,HANIMOGLU H,e al.Tissue and plasma thioredoxinreductase expression in patients with glioblastoma multiforme[J].Journal of Neurological Surgery-Part A Central European Neuro Surgery,2013,74:234-238.
[13] 李方超,曾慧慧,李贵新,等.血浆硫氧还蛋白还原酶在肺癌中表达的初步研究[J].实用肿瘤杂志,2014,29(3):231-233.LI Fangchao,ZENG Huihui,LI Guixin,et al.A prelininary study of plasmathioredoxin reductase expression in lung cancer[J].Journal of Practical Oncology,2014,29(3):231-233.
[14] 张百华,肖琴,丁衍,等.血浆硫氧还蛋白还原酶1在NSCLC中的诊断价值[J].临床与实验医学杂志,2016,15(15):1474-1478.ZHANG Baihua,XIAO Qin,DING Yan,et al.Plasma thioredoxin reductase 1 isa potential diagnostic biomarker for non-small cell lung cancer[J].Journal of Clinical and Experimental Medicine,2016,15(15):1474-1478.
[15] 林金端,刘红伟,张欣宁,等.Mybl2在不同病变程度宫颈组织中的表达[J].现代检验医学杂志,2017,32(2):141-143,145.LIN Jinduan,LIU Hongwei,ZHANG Xinning,et al.Expression level and clinical significance of Mybl2 in cervical tissue[J].J Mod Lab Med,2017,32(2):141-143,145.

相似文献/References:

[1]田英,王双勇,赵雅,等.宫颈癌组织细胞中Numb基因表达及相关性研究[J].现代检验医学杂志,2015,30(06):42.[doi:10.3969/j.issn.1671-7414.2015.06.012]
　TIAN Ying,WANG Shuang-yong,ZHAO Ya,et al.Study on Correlation and Expression of Numb Gene in Cervical Cancer[J].Journal of Modern Laboratory Medicine,2015,30(02):42.[doi:10.3969/j.issn.1671-7414.2015.06.012]
[2]林金端a,刘红伟a,张欣宁b,等.Mybl2在不同病变程度宫颈组织中的表达[J].现代检验医学杂志,2017,32(02):141.[doi:10.3969/j.issn.1671-7414.2017.02.039]
　LIN Jin-duana,LIU Hong-weia,ZHANG Xin-ningb,et al.Expression Level and Clinical Significance of Mybl2 in Cervical Tissues[J].Journal of Modern Laboratory Medicine,2017,32(02):141.[doi:10.3969/j.issn.1671-7414.2017.02.039]
[3]陈 慎,杜明君,宋雅琴.宫颈组织HPV DNA与血清Chemerin,Leptin水平联合检测对宫颈癌早期诊断的价值分析[J].现代检验医学杂志,2019,34(03):42.[doi:10.3969/j.issn.1671-7414.2019.03.010]
　CHEN Shen,DU Ming-jun,SONG Ya-qin.Value of Combined Detection of HPV DNA and Serum Levelsof Chemerin and Leptin in Early Diagnosis of Cervical Cancer[J].Journal of Modern Laboratory Medicine,2019,34(02):42.[doi:10.3969/j.issn.1671-7414.2019.03.010]
[4]周　静,李　智,周　玉,等.宫颈癌组织中 Ep-CAM和 Ki67的表达及临床意义[J].现代检验医学杂志,2019,34(06):24.[doi:10.3969 ／ j.issn.1671-7414.2019.06.006]
　ZHOU Jing,LI Zhi,ZHOU Yu,et al.Expression and Clinicd Value of Ep-CAM and Ki67 in the Cervial Carcinoma Tissue[J].Journal of Modern Laboratory Medicine,2019,34(02):24.[doi:10.3969 ／ j.issn.1671-7414.2019.06.006]
[5]徐晓锋a,王　纯b,卢国丰a,等.宫颈癌患者 Kruppel 样因子 6，p21 蛋白表达水平与病理特征及化疗敏感性的相关性分析[J].现代检验医学杂志,2020,35(06):12.[doi:doi:10.3969/j.issn.1671-7414.2020.06.004]
　XU Xiao-feng a,WANG Chun b,LU Guo-feng a,et al.Correlation Analysis of KLF6 and p21 Protein Expression Levels andPathological Features and Chemotherapy Sensitivity in Patientswith Cervical Cancer[J].Journal of Modern Laboratory Medicine,2020,35(02):12.[doi:doi:10.3969/j.issn.1671-7414.2020.06.004]
[6]高红敏,杨红英,刘　鑫.血清中 microRNA-106b 对宫颈癌患者的早期诊断及预后预测价值[J].现代检验医学杂志,2020,35(06):85.[doi:doi:10.3969/j.issn.1671-7414.2020.06.020]
　GAO Hong-min,YANG Hong-ying,LIU Xin.Value Analysis of Serum microRNA-106b in Early Diagnosis ofCervical Cancer[J].Journal of Modern Laboratory Medicine,2020,35(02):85.[doi:doi:10.3969/j.issn.1671-7414.2020.06.020]
[7]赵白信,于慧娟,焦方杰,等.经阴道彩色多普勒超声联合血清 miR-130a，miR-425-5p 水平检测对宫颈癌的诊断效能分析[J].现代检验医学杂志,2021,36(03):43.[doi:10.3969/j.issn.1671-7414.2021.03.010]
　ZHAO Bai-xin,YU Hui-juan,JIAO Fang-jie,et al.Analysis of Diagnostic Efficacy of Transvaginal Color Doppler UltrasoundCombined with Serum miR-130a and miR-425-5p Levels in Cervical Cancer[J].Journal of Modern Laboratory Medicine,2021,36(02):43.[doi:10.3969/j.issn.1671-7414.2021.03.010]
[8]张治洋,李功娟.10株宫颈癌细胞系中MALAT1的表达及其对顺铂敏感性的影响[J].现代检验医学杂志,2021,36(05):110.[doi:10.3969/j.issn.1671-7414.2021.05.024]
　ZHANG Zhi-yang,LI Gong-juan.Expression of MALAT1 in 10 Cervical Cancer Cell Lines and Its Effect onCisplatin Sensitivity[J].Journal of Modern Laboratory Medicine,2021,36(02):110.[doi:10.3969/j.issn.1671-7414.2021.05.024]
[9]郝艳芳,刘亚荣,黄玲玲,等.miRNA-195靶向调控 CCND2和 MYB抑制宫颈癌细胞增殖、迁移的机制研究[J].现代检验医学杂志,2022,37(01):130.[doi:10.3969/j.issn.1671-7414.2022.01.026]
　HAO Yan-fang,LIU Ya-rong,HUANG Ling-ling,et al.Study on the Mechanism of miRNA-195 Targeting CCND2 and MYB to Inhibit the Proliferation and Migration of Cervical Cancer Cells[J].Journal of Modern Laboratory Medicine,2022,37(02):130.[doi:10.3969/j.issn.1671-7414.2022.01.026]
[10]方　芳,吴　玲,魏善闯,等.宫颈癌患者血清LCN2水平表达与HPV病毒载量及临床分期的相关研究[J].现代检验医学杂志,2022,37(02):80.[doi:10.3969/j.issn.1671-7414.2022.02.017]
　FANG Fang,WU Ling,WEI Shan-chuang,et al.Correlation of Expression of Serum LCN2 Level with HPV Load and Clinical Stage in Patients with Cervical Cancer[J].Journal of Modern Laboratory Medicine,2022,37(02):80.[doi:10.3969/j.issn.1671-7414.2022.02.017]

备注/Memo

备注/Memo:
作者简介:顾益凤(1974-),女,硕士,副主任技师,从事肿瘤分子诊断方面的研究,E-mail:gyfkry@163.com。 通讯作者:刘红利(1975-),男,硕士,副主任技师,从事免疫学方面的研究,E-mail:1275930371@qq.com。 收稿日期:2018-12-08 修回日期:2018-12-31
更新日期/Last Update: 2019-04-30